In this regard, we synthesized and evaluated novel silyl-CHC compounds for their in vitro MCT1 inhibitory properties, in vitro effects on cancer cell proliferation and metabolism, and in vivo safety and efficacy in a WiDr tumor xenograft model. Here, SLC16A1 is linked to neoplasm.